JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Development of the G-Risk scoring system utilizing inflammatory and tumor biomarkers to improve prognostic accuracy in gastric cancer patients without lymphovascular invasion

  • 0Department of Oncology, Beidahuang Industry Group General Hospital, Harbin, China.
European Journal of Medical Research +

|

April 18, 2025

|

April 18, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

A new G-Risk scoring system accurately predicts survival for gastric cancer patients without lymphovascular invasion (LVI). This tool enhances prognostic accuracy and supports personalized treatment planning for better outcomes.

Area Of Science

  • Oncology
  • Biomarker Research
  • Prognostic Modeling

Background

  • Gastric cancer prognosis is complex, especially in patients without lymphovascular invasion (LVI).
  • Existing prognostic models may lack precision for specific patient subgroups.
  • Identifying reliable biomarkers is crucial for improving survival predictions.

Purpose Of The Study

  • To develop and validate the G-Risk scoring system, a novel prognostic model.
  • To enhance survival predictions for gastric cancer patients specifically excluding those with LVI.
  • To guide personalized treatment strategies based on refined risk stratification.

Main Methods

  • Biomarkers associated with survival were identified using univariate and multivariate Cox regression.
  • Inflammatory and tumor markers were analyzed to construct the G-Risk scoring system.
  • The system was specifically designed for patients without LVI to improve prognostic accuracy.

Main Results

  • The G-Risk score demonstrated strong predictive performance with an Area Under the Curve (AUC) of 0.660.
  • The score effectively stratified patients into distinct high-risk and low-risk groups.
  • Multivariate analysis confirmed the G-Risk score as an independent prognostic factor.

Conclusions

  • The G-Risk score is a validated and reliable prognostic tool for gastric cancer patients without LVI.
  • Clinical implementation can lead to more precise risk assessment and personalized treatment planning.
  • This tool has the potential to improve therapeutic outcomes and reduce unnecessary interventions.

Keywords: